Hua Zhong, Shengjie Sun, Jianhua Chen, Ziping Wang, Yanqiu Zhao, Guojun Zhang, Gongyan Chen, Ming Zhou, Jianying Zhou, Yingying Du, Lin Wu, Zhi Xu, Xiaodong Mei, Weidong Zhang, Jingdong He, Jiuwei Cui, Zhihong Zhang, Hui Luo, Weiyou Liu, Meili Sun, Jingxun Wu, Yongchun Shen, Shucai Zhang, Nong Yang, Mengzhao Wang, Junguo Lu, Kai Li, Weirong Yao, Qian Sun, Hongmei Yue, Lin Wang, Sheng Ye, Bin Li, Xibin Zhuang, Yueyin Pan, Min Zhang, Yongqian Shu, Zhiyong He, Lei Pan, Yang Ling, Shengming Liu, Qi Zhang, Shunchang Jiao, Baohui Han
BACKGROUND: Penpulimab is a novel programmed death (PD)-1 inhibitor. This study aimed to establish the efficacy and safety of first line penpulimab plus chemotherapy for advanced squamous non-small-cell lung cancer. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 3 clinical trial enrolled patients with locally advanced or metastatic squamous non-small-cell lung cancer from 74 hospitals in China. Eligible participants were aged 18-75 years, had histologically or cytologically confirmed locally advanced (stage IIIb or IIIc) or metastatic (stage IV) squamous non-small-cell lung cancer, were ineligible to complete surgical resection and concurrent or sequential chemoradiotherapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, did not have previous systemic chemotherapy for locally advanced or metastatic non-small-cell lung cancer, and had one or more measurable lesions according to RECIST (version 1...
January 31, 2024: Lancet Respiratory Medicine